2Scagiiotti GV, Parikh P, yon Pawel J, et al. Phase Ⅲ study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol, 2008, 26(21 ) : 3543 -3551.
6Scagliotti G. Optimizing chemotherapy for patients with advanced non-small cell lung cancer [ J ] . J Thorac Oncol, 2007, 2 (Suppl 2): S86-91.
7Devlin JG, Langer CJ. Salvage therapy with vinorelbine in advanced non-small cell lung cancer: a retrospective review of the Fox Chase Cancer Center experience and a review of the literature [ J].Clin Lung Cancer, 2007, 8(5): 319-326.
8Sekine I, Nokihara H, Sumi M, et ah Docetaxel consolidation therapy following cisplatin, vinorelbine, and concurrent thoracic radiotherapy in patients with unresectable stage Ⅲ non-small cell lung cancer [ J ] . J Thorac Oncol, 2006, 1(8): 810-815.
9Hirsh V, Desjardins P, Needles BM, et al. Oral versus intravenous administration of vinorelbine as a single agent for the first-line treatment of metastatic nonsmall cell lung carcinoma (NSCLC): a randomized phase Ⅱ trial [J].Am J Clin Oncol, 2007, 30(3): 245-251.
10Hosomi Y, Shibuya M. Non-cisplatin based chemotherapy in advanced non-small cell lung cancer [ J ] . GanTo Kagaku Ryoho, 2007, 34(4): 527-532.
2RIVORY LP, CLARKE SJ, BOYER M, et al. Highly sensitive analysis of the antifolate pemetrexed sodium, a new cancer agent, in human plasma and urine by high-performance liquid chro- matography[J]. J Chromatogr B Biomed Sci Appl, 2001, 765 (2): 135-140.
3HAMILTON CL, KIRKWOOD JA. Column-switching highper- formance liquid chromatographic method for the determination ofa thy-midylate synthase inhibitor, LY231514, an investigational agent for the treatment of solid tumors, in human plasma[J]. J Chro-matogr B Biomed Appl, 1994, 654(2): 297-303.
4MITA AC, SWEENEY CJ, BAKER SD, et ol. Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function[J]. J Clin Oncol, 2006, 24(4) : 552-562.
5ROWINSKY EK, BEERAM M, HAMMOND LA, et d. A phase I and pharmacokinetic study of pemetrexed plus irinotecanin patients with advanced solid malignancies[J]. Clin Cancer Res, 2007, 13(2): 532-539.
6SWEENEY CJ, TAKIMOTO CH, LATZ JE, et al. Two drug interaction studies evaluating the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or ibuprofen in patients with advanced cancer[J]. Clin Cancer Res, 2006, 12 (2) : 536-542.
